Research Progress on the Pathogenesis and Treatment of Neoatherosclerosis

Abstract

Neoatherosclerosis (NA) within stents has become an important clinical problem after coronary artery stent implantation. In-stent restenosis and in-stent thrombosis are the two major complications following coronary stent placement and seriously affect patient prognosis. As the common pathological basis of these two complications, NA plaques, unlike native atherosclerotic plaques, often grow around residual oxidized lipids and stent struts. The main components are foam cells formed by vascular smooth muscle cells (VSMCs) engulfing oxidized lipids at lipid residue sites. Current research mainly focuses on optical coherence tomography (OCT) and intravascular ultrasound (IVUS), but the specific pathogenesis of NA is still unclear. A thorough understanding of the pathogenesis and pathological features of NA provides a theoretical basis for clinical treatment. This article reviews the previous research of our research group and the current situation of domestic and foreign research.

References

[1] YahagiK, KolodgieFD, OtsukaF, et al.. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol, 2016, 13(2): 79-98

[2] MazinI, PaulG, AsherE, et al.. Neoatherosclerosis - From basic concept to clinical implication. Thromb Res, 2019, 178: 12-16

[3] BorovacJA, D’AmarioD, VergalloR, et al.. Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. Eur Heart J Cardiovasc Pharmacother, 2019, 5(2): 105-116

[4] LibbyP. Inflammation in Atherosclerosis—No Longer a Theory. Clin Chem, 2021, 67(1): 131-142

[5] LibbyP. Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond. Cells, 2021, 10(4): 951

[6] RaggiP, GenestJ, GilesJT, et al.. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis, 2018, 276: 98-108

[7] LibbyP, RidkerPM, HanssonGK. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473(7347): 317-325

[8] ChenZY, MatsumuraM, MintzGS, et al.. Prevalence and Impact of Neoatherosclerosis on Clinical Outcomes After Percutaneous Treatment of Second-Generation Drug-Eluting Stent Restenosis. Circ Cardiovasc Interv, 2022, 15(9): e011693

[9] MachF, BaigentC, CatapanoAL, et al.. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020, 41(1): 111-188

[10] RaberL, SerruysPW. Late vascular response following drug-eluting stent implantation. JACC Cardiovasc Interv, 2011, 4(10): 1075-1078

[11] AndreouI, StonePH. In-Stent Atherosclerosis at a Crossroads: Neoatherosclerosis or Paleoatherosclerosis?. Circulation, 2016, 134(19): 1413-1415

[12] YuanX, JiangM, FengH, et al.. The effect of sex differences on neointimal characteristics of in-stent restenosis in drug-eluting stents: An optical coherence tomography study. Heliyon, 2023, 9(8): e19073

[13] NakamuraD, DohiT, IshiharaT, et al.. Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis. EuroIntervention, 2021, 17(6): 489-496

[14] LeeSY, HurSH, LeeSG, et al.. Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. Circ Cardiovasc Interv, 2015, 8(2): e001878

[15] ToriiR, StettlerR, RaberL, et al.. Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions. Int J Cardiol, 2018, 272: 7-12

[16] ToriiS, JinnouchiH, SakamotoA, et al.. Drug-eluting coronary stents: insights from preclinical and pathology studies. Nat Rev Cardiol, 2020, 17(1): 37-51

[17] OtsukaF, ByrneRA, YahagiK, et al.. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J, 2015, 36(32): 2147-2159

[18] NakazawaG, OtsukaF, NakanoM, et al.. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol, 2011, 57(11): 1314-1322

[19] JangIK, TearneyGJ, MacNeillB, et al.. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation, 2005, 111(12): 1551-1555

[20] NakamuraD, AttizzaniGF, TomaC, et al.. Failure Mechanisms and Neoatherosclerosis Patterns in Very Late Drug-Eluting and Bare-Metal Stent Thrombosis. Circ Cardiovasc Interv, 2016, 9(9): e003785

[21] YabushitaH, BoumaBE, HouserSL, et al.. Characterization of human atherosclerosis by optical coherence tomography. Circulation, 2002, 106(13): 1640-1645

[22] AliZA, RolederT, NarulaJ, et al.. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv, 2013, 6(5): 507-517

[23] NuscaA, ViscusiMM, PiccirilloF, et al.. In Stent Neoatherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. Life (Basel), 2022, 12(3): 393

[24] ParkSJ, KangSJ, VirmaniR, et al.. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol, 2012, 59(23): 2051-2057

[25] BorovacJA, D’AmarioD, NiccoliG. Neoatherosclerosis and Late Thrombosis After Percutaneous Coronary Intervention: Translational Cardiology and Comparative Medicine from Bench to Bedside. Yale J Biol Med, 2017, 90(3): 463-470

[26] NakazawaG, VorpahlM, FinnAV, et al.. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging, 2009, 2(5): 625-628

[27] HandelsmanY, JellingerPS, GuerinCK, et al.. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract, 2020, 26(10): 1196-1224

[28] FarbA, KolodgieFD, HwangJY, et al.. Extracellular matrix changes in stented human coronary arteries. Circulation, 2004, 110(8): 940-947

[29] ArakiT, NakamuraM, SugiK. Characterization of in-stent neointimal tissue components following drug-eluting stent implantation according to the phase of restenosis using a 40-MHz intravascular ultrasound imaging system. J Cardiol, 2014, 64(6): 423-429

[30] CuiY, LiuY, ZhaoF, et al.. Neoatherosclerosis after Drug-Eluting Stent Implantation: Roles and Mechanisms. Oxid Med Cell Longev, 2016, 2016: 5924234

[31] WangH, WangQ, HuJ, et al.. Global research trends in in-stent neoatherosclerosis: A CiteSpace-based visual analysis. Front Cardiovasc Med, 2022, 9: 1025858

[32] WangZW, ChenJ, ZengZL, et al.. The LOX-1 receptor ectopically expressed in the liver alleviates atherosclerosis by clearing Ox-LDL from the circulation. Mol Med, 2022, 28(1): 26

[33] WangZW, GuoXP, ZhangQ, et al.. Elimination of Ox-LDL through the liver inhibits advanced atherosclerotic plaque progression. Int J Med Sci, 2021, 18(16): 3652-3664

[34] ZhangQ, DuGH, TongL, et al.. Overexpression of LOX-1 in hepatocytes protects vascular smooth muscle cells from phenotype transformation and wire injury induced carotid neoatherosclerosis through ALOX15. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(8): 166805